ECDA vs MCRB

Seres Therapeutics, Inc.

(MCRB) offers the better valuation at 12. 5x trailing P/E, making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Seres Therapeutics, Inc.

(MCRB) delivered a total return of -98. 2%, compared to -100. 0% for ECD Automotive Design, Inc. (ECDA). Over 10 years, the gap is even starker: MCRB returned -98. 3% versus ECDA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Seres Therapeutics, Inc.

(MCRB) is the lower-risk stock at 1. 69β versus ECD Automotive Design, Inc. 's 1. 88β — meaning ECDA is approximately 11% more volatile than MCRB relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc.

grew EPS 103. 4% year-over-year, compared to -540. 0% for ECD Automotive Design, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus -42. 8% for ECD Automotive Design, Inc. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ECDA leads at -15. 3% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — ECDA leads at 23. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Seres Therapeutics, Inc.

(MCRB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. ECD Automotive Design, Inc. (ECDA) carries a higher beta of 1. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCRB: -98. 3%, ECDA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ECDA (Consumer Cyclical) and MCRB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ECDA is a small-cap high-growth stock; MCRB is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.